Zeke Capital Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Zeke Capital Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,537	Closed	-$262K	–	335
2020 Q4	$262K	Sell	1,537 -106	-6%	-$15.7K	0.02%	221
2020 Q3	$231K	Buy	1,643 +215	+15%	+$32.7K	0.03%	193
2020 Q2	$229K	Buy	+1,428	New	+$194K	0.04%	169
2020 Q1	–	Sell	-5,343	Closed	-$689K	–	468
2019 Q4	$689K	Buy	5,343 +491	+10%	+$49.6K	0.06%	304
2019 Q3	$365K	Sell	4,852 -733	-13%	-$86.6K	0.03%	416
2019 Q2	$849K	Sell	5,585 -917	-14%	-$111K	0.08%	225
2019 Q1	$775K	Sell	6,502 -2,506	-28%	-$322K	0.07%	241
2018 Q4	$983K	Buy	9,008 +4,408	+96%	+$551K	0.09%	205
2018 Q3	$743K	Buy	4,600 +1,263	+38%	+$173K	0.06%	305
2018 Q2	$441K	Buy	3,337 +88	+3%	+$8.3K	0.04%	327
2018 Q1	$241K	Buy	+3,249	New	+$217K	0.02%	510

Other funds holding SRPT

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Zeke Capital Advisors's SRPT Position: Q1 2021 in Review

Zeke Capital Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2021, closing a stake of 1,537 shares — an estimated $262K sold.

Zeke Capital Advisors first reported a position in SRPT in Q1 2018 and held it in 11 quarters. The position peaked at $983K in Q4 2018. 366 funds tracked by Wall St. Rank hold SRPT as of Q1 2021.

Zeke Capital Advisors reported no remaining Sarepta Therapeutics position as of Q1 2021 after selling out during the quarter.
Zeke Capital Advisors sold 1,537 Sarepta Therapeutics shares in Q1 2021, an estimated $262K.
Zeke Capital Advisors first reported a position in Sarepta Therapeutics in Q1 2018 and held it in 11 quarters.
Zeke Capital Advisors's Sarepta Therapeutics position peaked at $983K in Q4 2018.
366 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2021.

Based on Zeke Capital Advisors's 13F filing for Q1 2021, filed 21 Apr 2021.